BioLife Sciences Inc. (“BioLife” or the “Company”) (OTCPK: BLFE) specializes in moving innovative products from the lab or small-scale production into broader market adoption. Its core business develops, licenses, and distributes antimicrobial products and disruptive technology.

On the surface, BioLife appears much more complicated than it seems. The Company is a commercialization accelerator, licensor, and developer of innovative and disruptive technologies for the healthcare, beauty, and food and beverage sectors.

Current product focus includes copper infusion for antimicrobial product development and recently announced Hemp-based products.

BioLife aims to enrich the lives of our customers, communities, and colleagues, and we know that we will not thrive unless the communities around us equally thrive. We conduct our business in a socially responsible and ethical manner with a strong focus on producing sustainable, locally made, and ethically sourced products.

Copper Product Infusion

A visit to the site of copper mining giant Teck prominently discusses the very consumer antimicrobial product market BioLife is developing and growing, including:

• Phone Cases
• Socks
• Pens
• Pillowcases
• Skin Cream
• Combs

And likely the most significant growth area in the Copper and health area? Healthcare-acquired infections continue to be one of the leading causes of death in Canada, and many innovative copper products are in the works and stand to make a significant impact in the years to come.

Copper Technology “Closeology”/Life Sciences Division

Copper ions are proven pathogen killers and have documented antimicrobial benefits.

If BioLife were a mine near a Teck property it could benefit through location “Closeology.” The direction of the two companies—one mammoth, one not, yet— could still share the term in a technology sense. And BioLife is way cheaper on a per-share basis.

One example is BLFE’s recent announcement of Microfiber Towel development which is forecast to be nearly USD$800 million by 2026, representing a modest yet solid 2.5% CAGR. Other markets will raise that growth significantly.

BioLife Copper-Infused Microfiber Towels are designed to provide an electrostatic charge that attracts even the most minor pieces of dirt, grease, and moisture. The Copper then reinforces the cleaned area with antimicrobial shielding, providing long-lasting protection.

Development Association’s Antimicrobial Copper Alloys- Group 1 (EPA Reg. No. 82012-1), which is made of at least 95.6 percent copper, is now listed as a supplemental residual antimicrobial product for the coronavirus on the EPA website.

So as previously stated, the use of Copper is becoming pervasive and pretty much mainstream. Companies like BLFE provide a proxy for various Copper sectors and potentially a merger or takeover candidate. The Company is working apace to develop and release ‘disruptive’ copper products, which will, at some point, bring it more attention. A planned listing on the OTCQB market will certainly help in that endeavor.

CBD Product Initiatives

The development will include THC-free products in medical products, beverages, creams, salves, efficacious supplements, superfood concentrates, nutraceutical formulations, and advanced orthomolecular and natural health products.

Nika Jaksic, COO of BioLife Sciences, stated, “We believe CBD sales will continue their strong upward trend with current e-commerce sales soon being joined by consumers returning to brick and mortar options, as the pandemic wanes and disposable incomes continue to rise. CBD and other cannabinoids found in the hemp plant are beneficial supplements, as evidenced by ongoing studies highlighting that we haven’t even begun to understand all these healing cannabinoids’ abilities and uses.”

Bottom Line

At the outset, we posited the growth of BLFE, which seemed and is wide-ranging but based on the simplicity of the health benefits of Copper infusion and as a product additive. The endorsement of Copper giants such as Teck mining adds serious credence to the potential of Copper use in countless life, pain, and health-enhancing products.

BioLife filed Form 1-A with the Securities and Exchange Commission (SEC) seeking to raise $20 million under a Tier I Regulation A+ offering.

The Reg A+ filing was accepted by the SEC on July 15th, 2022, and is structured to raise $20 million through the sale of our common stock at a price per share between $.05 and $.50. The final price will be set once the offering statement has been qualified by the SEC. The money raised would fund and expand existing operations, payoff company debt, and complete additional acquisitions.

At the very least, BLFE deserves a watch, if not a potential purchase. We’ll keep on it. You should as well.

Disclaimer:

Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.

All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated eight and one dollars and thirty eight cents cash for the creation and dissemination of this content by a third party Guerrilla Capital and Ryan Yanch.

This material does not represent a solicitation to buy or sell any securities. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.

The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.

Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post BioLife Sciences Inc. (OTC Pink: BLFE): An Innovative Developer in the Antimicrobial Product Market appeared first on Spotlight Growth.